5832 related articles for article (PubMed ID: 3102149)
1. Augmentation of natural immunity and correlation with tumor response in melanoma patients treated with human lymphoblastoid interferon.
Neefe JR; Phillips EA; Treat J
Diagn Immunol; 1986; 4(6):299-305. PubMed ID: 3102149
[TBL] [Abstract][Full Text] [Related]
2. Preliminary observations of immunomodulatory activity of lymphoblastoid interferon-alpha administered every other day or weekly.
Neefe JR; Sullivan JE; Silgals R
J Biol Response Mod; 1983; 2(5):441-9. PubMed ID: 6644348
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
4. Augmented immunity in cancer patients treated with alpha-interferon.
Neefe JR; Sullivan JE; Ayoob M; Phillips E; Smith FP
Cancer Res; 1985 Feb; 45(2):874-8. PubMed ID: 3967248
[TBL] [Abstract][Full Text] [Related]
5. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.
Hersey P; Coates A; Rallings M; Hall C; MacDonald M; Spurling A; Edwards A; McCarthy WH; Milton GW
J Biol Response Mod; 1986 Jun; 5(3):236-49. PubMed ID: 3487622
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cell activity in tumor-draining lymph nodes: investigations in patients with malignant melanoma and head and neck cancer.
Micksche M; Vinzenz K; Kokoschka EM; Kokoschka R
Nat Immun Cell Growth Regul; 1985; 4(6):315-27. PubMed ID: 4088287
[TBL] [Abstract][Full Text] [Related]
7. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
Koren HS; Brandt CP; Tso CY; Laszlo J
J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
[TBL] [Abstract][Full Text] [Related]
8. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line.
Howell DN; Andreotti PE; Dawson JR; Cresswell P
J Immunol; 1985 Feb; 134(2):971-6. PubMed ID: 3871222
[TBL] [Abstract][Full Text] [Related]
9. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
10. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
Metha BA; Advani SH; Nadkarni SJ
Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of norepinephrine-mediated inhibition of human NK cytotoxic functions: inhibition of cytokine secretion, target binding, and programming for cytotoxicity.
Gan X; Zhang L; Solomon GF; Bonavida B
Brain Behav Immun; 2002 Jun; 16(3):227-46. PubMed ID: 12009684
[TBL] [Abstract][Full Text] [Related]
13. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
14. Production of tumor necrosis factor-alpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro.
Ghoneum M; Jewett A
Cancer Detect Prev; 2000; 24(4):314-24. PubMed ID: 11059563
[TBL] [Abstract][Full Text] [Related]
15. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells.
Okabe M; Gomi K; Morimoto M; Nakamizo N
Jpn J Cancer Res; 1985 Jul; 76(7):608-17. PubMed ID: 3928557
[TBL] [Abstract][Full Text] [Related]
16. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
Rice GP; Casali P; Merigan TC; Oldstone MB
Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
Lichtenstein A; Spina C; Berek JS; Jung T; Zighelboim J
Cancer Res; 1988 Oct; 48(20):5853-9. PubMed ID: 3167841
[TBL] [Abstract][Full Text] [Related]
19. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
[TBL] [Abstract][Full Text] [Related]
20. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
